Finnzymes have developed a range of reagents,consumables and instrumentation to allow fastPCR in inhibiting conditions. Here we describean application for amplifying exogenous andhuman genomic DNA from whole blood withoutthe need for DNA purification, and use ofspecial buffers or complicated protocols.Finnzymes' solution for High Performance (HP)-PCR results in faster amplification with betteryields for raw blood samples as compared withconventional methods for PCR.
Finnzymes’ HP-PCR is a tripartite solution focused onspeeding up a PCR and providing marked improvementsin yield while maintaining high fidelity. The uniquecombination of our highly processive PhusionTM DNAPolymerases, quick PikoTM Thermal Cyclers and ultra-thinwalled UTWTM tubes provides considerable benefits to thespeed, yield, fidelity, specificity and robustness of PCR.Central to these improvements is our Phusion technology,which enhances activity by way of a double-strandedDNA-binding domain bound to a highly engineeredproofreading polymerase. This dsDNA-binding domainallows for ultra-robust reactions by tethering thepolymerase to the duplex DNA, driving much higherassociation constants, so the effects of conventionalinhibitors of PCR are significantly reduced1. Here wedescribe one such application, a simple protocol for robustamplification of DNA from whole blood. Whole blood isoften used in clinical diagnostics and as a DNA source forPCR tests. Unfortunately, Taq DNA polymerase, the mostcommonly used enzyme for PCR, is known to becompletely inhibited by even small quantities of wholeblood in the reaction2. Several strategies have been usedto overcome this difficulty, including the use of specializedpurifications, buffers and pretreatments3,4, but all of thesemethods have drawbacks, adding time and cost, and oftenproducing inconsistent results. As a consequence,purification of genomic DNA from whole blood remains acommon practice even though it adds considerable timeand expense to the test.